Drug Trial Radar · NCT06340958
A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder
Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
99
Actual
Start
Mar 18, 2024
Primary completion
Jun 6, 2025
Study completion Nov 25, 2025
Sponsor
- Lead sponsor
- Clexio Biosciences Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is a Phase 2, double-blind, randomized, placebo-controlled study in Major Depressive Disorder (MDD) participants with an inadequate response to standard antidepressants The objective of the study is to assess CLE-100 (oral esketamine) for the treatment of MDD in participants currently treated with an oral antidepressant medication and who have an inadequate response to at least 2 antidepressants.
Conditions
- Adjunctive Treatment of Major Depressive Disorder (MDD)
Interventions
CLE-100Drug
1 tablet of CLE-100 administered once daily
PlaceboDrug
1 tablet of placebo administered once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) ScoreTime frame: 29 days
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
Clinical Site 139
La Jolla, California
Clinical Site 131
Lafayette, California
Clinical Site 130
Upland, California
Clinical Site 102
Hollywood, Florida
Clinical Site 105
Lauderhill, Florida
Clinical Site 140
Miami Springs, Florida
Clinical Site 132
Pensacola, Florida
Clinical Site 118
Atlanta, Georgia
Clinical Site 138
Marietta, Georgia
Clinical Site 114
Savannah, Georgia
Clinical Site 127
Chicago, Illinois
Clinical Site 120
Elgin, Illinois
Clinical Site 108
Gaithersburg, Maryland
Clinical Site 116
Flowood, Mississippi
Clinical Site 126
O'Fallon, Missouri
Clinical Site 101
Toms River, New Jersey
Clinical Site 103
Beachwood, Ohio
Clinical Site 119
North Canton, Ohio
Clinical Site 135
Oklahoma City, Oklahoma
Clinical Site 107
Austin, Texas
Clinical Site 137
Plano, Texas
Clinical Site 117
Murray, Utah
Clinical Site 115
Bellevue, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.